<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Drug</th><th>Group 1 <break/>across dose</th><th>Group 2 <break/>across dose</th><th>Variance <break/>estimate</th><th>Effect <break/>size <italic>f</italic></th><th>A priori <break/>power</th><th>Samples <break/>per group</th></tr></thead><tbody><tr><td rowspan="8">GDC-0879</td><td rowspan="4">shBRAF (+ Dox)</td><td rowspan="4">shBRAF (- Dox)</td><td>2%</td><td>1.77874</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.23717</td><td>84.6%</td><td>6</td></tr><tr><td>28%</td><td>0.12705</td><td>81.2%</td><td>19</td></tr><tr><td>40%</td><td>0.08894</td><td>80.4%</td><td>38</td></tr><tr><td rowspan="4">shCRAF (+ Dox)</td><td rowspan="4">shCRAF (- Dox)</td><td>2%</td><td>4.97629</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.66351</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>0.35545</td><td>88.0%</td><td>3</td></tr><tr><td>40%</td><td>0.24881</td><td>80.9%</td><td>5</td></tr><tr><td rowspan="8">PLX4720</td><td rowspan="4">shBRAF (+ Dox)</td><td rowspan="4">shBRAF (- Dox)</td><td>2%</td><td>3.13815</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.41841</td><td>96.2%</td><td>3</td></tr><tr><td>28%</td><td>0.22415</td><td>86.2%</td><td>7</td></tr><tr><td>40%</td><td>0.15690</td><td>82.9%</td><td>13</td></tr><tr><td rowspan="4">shCRAF (+ Dox)</td><td rowspan="4">shCRAF (- Dox)</td><td>2%</td><td>18.2081</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>2.42775</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>1.30058</td><td>99.9%</td><td>3</td></tr><tr><td>40%</td><td>0.91040</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap>